Aptamers are short, synthetic single-stranded DNA or RNA molecules that can bind to a specific target molecule. They have several advantages over traditional monoclonal antibodies such as low immunogenicity, high tissue penetration, ease of chemical modification and production through cell-free synthesis. These key characteristics have enabled their use in medical diagnostics, research and clinical development.
The global Aptamers market is estimated to be valued at US$ 7217.85 Mn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Aptamers market are ZOLL Medical Corporation, Stryker, Brunswick MedTech, Michigan Instruments, SunLife Sciences Pvt Ltd., CPR Medical Devices, Inc., Medtronic, Faith Group, Nihon Kohden Corporation, SCHILLER Americas Inc. The demand for aptamers is growing owing to increasing investments by pharmaceutical and biotechnology companies in R&D of targeted therapeutics. Aptamers are increasingly being used as alternative to monoclonal antibodies in disease diagnostics and treatment due to unique advantages over antibodies. Technological advancements in SELEX technology have enabled generation of aptamers against complex molecular targets such as whole cells accelerating their clinical research.
Market Trends
Growing demand for personalized medicine is driving the development of aptamer-based therapeutics and diagnostics. Several biotechnology companies are developing aptamer-drug conjugates and aptamer-siRNA chimeras for targeted delivery of therapeutic payloads. Nanoparticle-aptamer bioconjugates are also being explored as tumor-targeted drug carriers. Advancements in SELEX technology such as Microfluidic SELEX, Cell-SELEX and toggle-SELEX have improved the efficiency of aptamer selection against disease-specific biomarkers.
Market Opportunities
Rising focus on precision medicine gives opportunities to develop Aptamers Market Size diagnostic kits for point-of-care testing of cancers, infectious diseases and genetic disorders. Increasing R&D investments by pharma companies in developing aptamer therapeutics against cancer, macular degeneration and thrombotic disorders.
Impact of COVID-19 on Aptamers Market
The COVID-19 pandemic had a significant impact on the aptamers market. During the initial phase of the pandemic, manufacturing and supply chain disruptions impacted market growth. Stringent lockdowns and social distancing measures enforced across regions stalled new research and product development activities. This adversely affected sales of research reagents and diagnostic kits. However, with the growing emphasis on accelerating point-of-care testing and development of rapid screening solutions for SARS-CoV-2 virus detection, demand for aptamers picked up significantly post 2020. Ongoing research on aptamer-based therapeutics and diagnostics for COVID-19 is expected to further drive market expansion in coming years. companies are likely to prioritize development of novel aptamer-based platforms to address unmet needs emerging from this pandemic.
North America holds the major share of the aptamers market in terms of value. This is attributed to presence of leading research institutes and biotech companies, growing R&D investments for development of novel aptamer-based technologies, and availability of advanced healthcare infrastructure. The U.S. accounts for the largest market in the region. Rising prevalence of chronic diseases and growing focus on precision medicine are fueling demand for aptamer-based solutions in the country. Asia Pacific is projected to be the fastest growing regional market between 2024 and 2031. This can be accredited to improving healthcare standards, increasing research funding, and growing awareness about clinical applications of aptamers. China, Japan and India are expected to offer significant lucrative opportunities over the coming years.
Explore more information on this topic, Please visit -
